section name header

Pronunciation

fe-LOE-di-peen

Classifications

Therapeutic Classification: antianginals, antihypertensives

Pharmacologic Classification: calcium channel blockers

Indications

REMS


Action

  • Inhibits the transport of calcium into myocardial and vascular smooth muscle cells, resulting in inhibition of excitation-contraction coupling and subsequent contraction.
Therapeutic effects:
  • Systemic vasodilation resulting in decreased BP.
  • Coronary vasodilation resulting in decreased frequency and severity of attacks of angina.

Pharmacokinetics

Absorption: Well absorbed after oral administration but extensively metabolized, resulting in bioavailability.

Distribution: Unknown.

Protein Binding: >99%.

Metabolism/Excretion: Mostly metabolized; minimal amounts excreted unchanged by kidneys.

Half-Life: 11–16 hr.

Time/Action Profile

(antihypertensive effect)

ROUTEONSETPEAKDURATION
PO1 hr2–4 hrup to 24 hr





Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

CV: peripheral edema, ARRHYTHMIAS, chest pain, HF, hypotension, palpitations, syncope, tachycardia

Derm: sweating, dermatitis, erythema multiforme, flushing, photosensitivity, pruritus/urticaria, rash, STEVENS-JOHNSON SYNDROME (SJS)

EENT: blurred vision, disturbed equilibrium, epistaxis, tinnitus

Endo: gynecomastia, hyperglycemia

GI: liver enzymes, anorexia, constipation, diarrhea, dry mouth, dyspepsia, gingival hyperplasia, nausea, vomiting

GU: dysuria, nocturia, polyuria, sexual dysfunction, urinary frequency

Hemat: anemia, leukopenia, thrombocytopenia

Metab: weight gain

MS: joint stiffness, muscle cramps

Neuro: headache, abnormal dreams, anxiety, confusion, dizziness, drowsiness, dysgeusia, paresthesia, psychiatric disturbances, tremor, weakness.

Resp: cough, dyspnea

Interactions

Drug-drug:

Route/Dosage

Availability

(Generic available)

Assessment

Lab Test Considerations:

Implementation

Patient/Family Teaching

Evaluation/Desired Outcomes

Canadian Brand Names

Plendil